Order Article Reprints

Gounant V, Duruisseaux M, Soussi G, Van Hulst S, Bylicki O, Cadranel J, Wislez M, Trédaniel J, Spano J-P, Helissey C, et al. Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers. 2021; 13(5):1040. https://doi.org/10.3390/cancers13051040

Gounant, Valérie, Michael Duruisseaux, Ghassen Soussi, Sylvie Van Hulst, Olivier Bylicki, Jacques Cadranel, Marie Wislez, Jean Trédaniel, Jean-Philippe Spano, Carole Helissey, and et al. 2021. "Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients" Cancers 13, no. 5: 1040. https://doi.org/10.3390/cancers13051040

Gounant, V., Duruisseaux, M., Soussi, G., Van Hulst, S., Bylicki, O., Cadranel, J., Wislez, M., Trédaniel, J., Spano, J.-P., Helissey, C., Chouaid, C., Molinier, O., Dhalluin, X., Doucet, L., Hureaux, J., Cazes, A., & Zalcman, G. (2021). Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers, 13(5), 1040. https://doi.org/10.3390/cancers13051040